Skip to content
naulon
Not checkedNot checked for notices yet.

Combined versus single locoregional therapy in the treatment of unresectable hepatocellular carcinoma

Moustafa H.M. Othman, Amr F. Mourad, Mohamed M.H. Abd Ellah and 1 more

The Egyptian Journal of Radiology and Nuclear Medicine · 2014

doi:10.1016/j.ejrnm.2014.02.018 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Introduction: Surgical and locoregional therapies are different options in HCC treatment, several locoregional techniques are used. Purpose: This study aimed to assess the effectiveness of transarterial chemoembolization (TACE), radiofrequency ablation (RFA) and combined therapy, in HCC management. Materials and methods: The study was conducted at our University Hospital, from August 2011 to February 2013. It included 60 patients with HCC (40 males and 20 females, age ranged between 45 and 70 years). Patients were classified into 3 groups, group 1 treated with TACE, group 2 with RFA, and group 3 with both techniques. Response was assessed by triphasic CT and alpha fetoprotein. Patients were classified into good and poor responders after one and six months and one year. Patients’ survival and incidence of recurrence were recorded. Results: The percentage of good responders was greater with combined therapy than with TACE and RFA (90%, 70%, and 60% respectively). The overall survival was 75% and the recurrence free survival was 60% in TACE, 90%, and 45% in RFA and 95% and 90% in combined therapy respectively. Conclusion: Combined therapy is superior regarding good response, overall survival, and free recurrence survival than either TACE or RFA alone.

Abstract licence: CC BY-NC-ND

References28

    28 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.